| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5598219 | Annals of Vascular Surgery | 2017 | 8 Pages |
Abstract
Compared to our patients recruited for the INNOVATION trial, the patients after CE Mark approval had significantly more challenging access routes reflecting the difficulties of “real-world” conditions. Despite frequent adjunctive procedures in group CM, the early performance of the endograft was encouraging so far. Long-term surveillance of those patients remains mandatory.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Masayuki Sugimoto, Giovanni F. Torsello, Giovanni B. Torsello, Martin Austermann, Arne Stachmann, Theodosios Bisdas,